Ruxolitinib for symptom control in patients with Chronic Lymphocytic leukemia: A Phase II Trial

BACKGROUND: Disease-related symptoms impair the quality of life of countless patients with chronic lymphocytic leukemia (CLL) who do not require systemic therapy. Currently available therapies are not specifically aimed at symptom control. Because stimulation of the B-cell receptor activates Janus k...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Preetesh, Keating, Michael, Renner, Sarah, Cleeland, Charles, Xuelin, Huang, Gonzalez, Graciela Nogueras, Harris, David, Li, Ping, Liu, Zhiming, Veletic, Ivo, Rozovski, Uri, Jain, Nitin, Thompson, Phillip, Bose, Prithviraj, DiNardo, Courtney, Ferrajoli, Alessandra, O’Brien, Susan, Burger, Jan, Wierda, William, Verstovsek, Srdan, Kantarjian, Hagop, Estrov, Zeev
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356368/
https://www.ncbi.nlm.nih.gov/pubmed/28089238
http://dx.doi.org/10.1016/S2352-3026(16)30194-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356368/
https://www.ncbi.nlm.nih.gov/pubmed/28089238
http://dx.doi.org/10.1016/S2352-3026(16)30194-6

Ejemplares similares